SEATTLE, July 08, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and […]
Conversion of C$420 million subordinated convertible debentures and preferred shares into new equityNew cash equity investment commitment of C$100 millionExtension […]